Liposomal Bupivacaine Block No Aid for Cesarean Pain

Share this content:
Liposomal Bupivacaine Block No Aid for Cesarean Pain
Liposomal Bupivacaine Block No Aid for Cesarean Pain

THURSDAY, Aug. 16, 2018 (HealthDay News) -- A liposomal bupivacaine incisional block at the time of cesarean delivery does not improve pain scores in the first 48 hours postoperatively, according to a study published in the July issue of Obstetrics & Gynecology.

Malavika Prabhu, M.D., from Massachusetts General Hospital in Boston, and colleagues evaluated whether a liposomal bupivacaine incisional block decreases postoperative pain after cesarean delivery. Eighty women were randomized to either liposomal bupivacaine or placebo infiltrated into the fascia and skin at the surgical site, before fascial closure. One woman in the liposomal bupivacaine group was later excluded.

The researchers found that the median pain score with movement at 48 hours postoperatively was 4 (in an 11-point scale) in the liposomal bupivacaine group and 3.5 in the placebo group (P = 0.72). During the first 48 hours postoperatively, the median opioid use was the same (37.5 morphine milligram equivalents) in the two groups (P = 0.44).

"Compared with placebo, a liposomal bupivacaine incisional block at the time of cesarean delivery resulted in similar postoperative pain scores in the first 48 hours postoperatively," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Device sensitivity/specificity 100/97.8 percent for vision-threatening diabetic retinopathy

Altered Gut Microbiome Seen in Patients With Active Lupus

Altered Gut Microbiome Seen in Patients With Active ...

Patients with lupus had fivefold greater representation of Ruminococcus gnavus

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer

Combo Regimens Effective for Tx of Metastatic Renal ...

Two large trials show benefits for pembrolizumab-axitinib and avelumab-axitinib versus sunitinib

is free, fast, and customized just for you!




Already a member?

Sign In Now »